Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Milestone Pharmaceuticals has enrolled its first European participant in the ReVeRA-301 Phase 3 clinical trial evaluating etripamil nasal spray for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial aims to enroll approximately 150 patients across multiple sites including the Dutch Cardiovascular Investigator Network to …
Nuvectis Pharma, a clinical-stage biopharmaceutical company focused on complement-related conditions and oncology, announced participation in the Maxim Growth Summit 2026. Senior management will present in a panel discussion focusing on immunology and inflammation therapies. The company highlighted its lead drug candidate ciprocopan recently approv…
GlobalFoundries (Nasdaq: GFS) announced its new FDX Fusion FD-SOI semiconductor platform tailored for Physical AI workloads, targeting manufacturing start in 2028 at its Dresden facility. The 7nm-class technology aims to deliver superior performance, power efficiency, and system integration for automotive, industrial, consumer, and edge AI markets,…
XMax Inc., a NASDAQ-listed distributor of furniture and AI software provider, announced the acquisition of Hexa Creation Inc., a U.S.-based developer of 1200V vertical GaN power semiconductor technology. This strategic move aims to expand XMax's AI ecosystem into high-voltage power infrastructure targeting AI data centers and other applications lik…
Stride, Inc., a leading education technology company, announced the appointment of Dr. Steven Guttentag and Dylan Haggart to its Board of Directors. Alongside these appointments, Stride is forming a Capital Allocation Committee to evaluate its capital structure and priorities, aiming to maximize long-term shareholder value. The company plans to eng…
Quince Therapeutics has rebranded as IRulya Therapeutics following a merger with Orphai Therapeutics and a significant capital raise. The company will trade on Nasdaq under the ticker IRLA, focusing on the clinical development of LAM-001, a novel inhaled formulation of rapamycin targeting mTOR pathways implicated in several severe pulmonary disease…
Filana Therapeutics, a biotechnology firm focused on developing therapies for TSC-related epilepsy, announced its management team's participation in the 2026 Maxim Growth Summit in New York from October 12-14, 2026, where they will engage in one-on-one investor meetings.
VCI Global Limited announced clarification on its US$125 million standby equity purchase facility with Hudson Global Ventures, highlighting that no funds have been drawn to date. The flexible facility allows VCI to access capital over 36 months, aligning with its growth strategies in AI infrastructure and renewable energy projects. The company emph…
Profound Medical Corp. and Telix Pharmaceuticals have entered a co-education agreement to educate healthcare professionals on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO platform for prostate cancer care. The collaboration aims to increase physician awareness, facilitate better pati…
Eli Lilly's cardiometabolic franchise continues to dominate industry headlines and company sales. The stock has pulled back from highs but fundamentals and technicals suggest the recent dip is a buying opportunity for a measured 180-day trade. Trade plan, rationale, catalysts, and balanced risks provided.
After a transformational asset sale earlier this year the market is effectively pricing Vistance's remaining networking and access businesses at roughly 2.5x EV/EBITDA and under 0.6x sales. With zero reported debt, a strong current ratio and recent special distributions, VISN looks like a tactical long around current levels. This trade idea lays ou…
Aura Minerals Inc. announced preliminary Q3 2026 production results achieving a record 95,557 gold equivalent ounces (GEO), representing a 27% increase over Q2 2026 and 29% above Q3 2025. Nine-month 2026 production also reached a historic high of over 253,000 GEO, driven by higher grades and throughput primarily at Borborema, Aranzazu, and MSG mine…
VenHub Global, Inc. announced the continued expansion of its intellectual property program focused on autonomous retail Smart Store technology. The company's patent portfolio and planned filings encompass innovations in modular store infrastructure, robotics, AI-driven operations, inventory management, and security systems designed to enhance unatt…
Watsco, Inc., the largest distributor in the North American HVAC market, announced it will release its Q3 2026 earnings before market open on October 27, 2026, followed by a conference call with management. The company highlights its history of growth through organic development and acquisitions, its strong balance sheet, and ongoing investment in …
I am upgrading Pfizer (PFE) from bearish to a cautious bullish stance. The stock offers a mix of reliable free cash flow ($10.99B), a rich dividend yield (~6.14%), and accelerating oncology revenues that should support multiple expansion. This is a trade idea for investors willing to accept company- and sector-specific regulatory risk in exchange f…
The Elmet Group is uniquely positioned as a U.S.-centric tungsten and precision components supplier with direct Department of Defense backing, a freshly solidified supply line via Masan, and a tight float that can amplify upside. We initiate a position with clear entry, stop and target levels and a plan that spans from tactical to position-sized ho…
Alterity Therapeutics, a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases like Multiple System Atrophy (MSA), announced that its CEO, Dr. David Stamler, will present at the Canaccord Genuity Drug and Device Conference. The company is preparing to initiate a Phase 3 pivotal trial for its lead drug …
Sagimet Biosciences announced that its license partner Ascletis demonstrated positive 52-week Phase 3 open-label extension results for denifanstat, an oral fatty acid synthase inhibitor, in treating moderate to severe acne vulgaris. The drug showed continuing efficacy and safety with significant improvements in clinical endpoints. Sagimet is now ad…
Teva Pharmaceutical Industries Ltd. announced FDA approval of WELTRUZA™, the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for treating schizophrenia in adults. This new treatment requires no loading doses, no oral supplementation, and no post-injection monitoring. The approval was based on positive Phase…
Aurora Mobile Limited (NASDAQ: JG) has partnered with Yunnan Shennong Agricultural Industry Group to deploy its JPush intelligent push notification solution. This collaboration aims to improve the reliability and timeliness of critical business alerts within Shennong Group's digital agriculture value chain, addressing challenges posed by mobile app…
Wrap Technologies, a Nasdaq-listed provider of non-lethal response technologies, announced the appointment of John "Chappy" Chapman as Vice President of Training and Missions. Chapman brings over 30 years of law enforcement and tactical training expertise to lead the scaling and standardization of Wrap's non-lethal response training programs across…
X4 Pharmaceuticals will host a virtual Investor Day on October 29, 2026, discussing the development of mavorixafor, an oral CXCR4 antagonist in late-stage trials for treating chronic neutropenia. The event features management updates on the Phase 3 4WARD trial, plans for a Phase 2 trial combining mavorixafor with G-CSF, and presentations by hematol…
Manhattan Bridge Capital, Inc. has announced that its Board has approved increasing its common share repurchase program from 100,000 to 250,000 shares and extended the program for an additional 12 months. The company offers short-term secured loans to real estate investors in the New York metropolitan area and Florida. This buy-back initiative refl…
Barrick Mining Corporation will announce its third quarter 2026 financial results on November 9, 2026, before market open. The company will also host a live webcast and presentation followed by a Q&A session with analysts. As a major global gold and copper mining company, Barrick continues its disciplined growth and responsible mining operations ac…
Balchem Corporation announced it will hold a conference call on October 23, 2026, to discuss its third quarter financial results. The company's leadership, including CEO Ted Harris and CFO Martin Bengtsson, will host the call. Results and financial exhibits will be published prior to the call and available on Balchem's website. The company operates…
